AbbVie Inc. (ABBV)
| Market Cap | 366.77B |
| Revenue (ttm) | 56.33B |
| Net Income (ttm) | 4.24B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.39 |
| PE Ratio | 86.99 |
| Forward PE | 16.93 |
| Dividend | $6.56 (3.16%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 4,334,042 |
| Open | 209.39 |
| Previous Close | 210.01 |
| Day's Range | 207.51 - 211.02 |
| 52-Week Range | 153.58 - 218.66 |
| Beta | 0.60 |
| Analysts | Strong Buy |
| Price Target | 212.70 (+2.38%) |
| Earnings Date | Apr 25, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for ABBV stock is "Strong Buy." The 12-month stock price forecast is $212.7, which is an increase of 2.38% from the latest price.
News
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i...
My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 11 Buys
February investments fell below $1,000, mainly in BDCs like Owl Rock Capital and Ares Capital, boosting annual dividend income by $77. Dividend income hit a new February record of $505, up 5% Y/Y driv...
Widely used drugs on US imports list from Europe
Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.
ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positi...
Drugmakers agree to participate in second round of price negotiations
All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of price talks have agreed to participate in the negotiation process, a federal h...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk. AbbVie's will pay $350 million up...
Calls of the Day: United Airlines, Delta, IBM, Abbvie, Uber
The Investment Committee debate the latest Calls of the Day.
AbbVie Inc. (ABBV) Leerink Partners Global Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV) Leerink Partners Global Healthcare Conference March 11, 2025 8:40 AM ET Company Participants Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar -...
Siri & Glimstad Defeats AbbVie's Motion to Dismiss Illinois GIPA Lawsuit
Call to Action: Join Open Class Action Against AbbVie CHICAGO, IL / ACCESS Newswire / March 11, 2025 / Recently, the Northern District of Illinois denied AbbVie's motion to dismiss a lawsuit alleging ...
Darst's Stock Picks: GOLD, EL, ABBV
"We currently advise gradually shifting exposure away from high-growth areas toward more value and defensive sectors," notes David Darst. He discusses finding opportunities in an uncertain market.
AbbVie Inc. (ABBV) TD Cowen 45th Annual Health Care Conference (Transcript)
AbbVie Inc. (NYSE:ABBV) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Company Participants Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R.
5 Big Biopharmaceutical Stocks That Are Finding Favor
AbbVie, Gilead Sciences, Amgen, and Johnson & Johnson have held steady amid a fluctuating market.
The Dividend Aristocrats Ranked By Quality Scores: March 2025
S&P Dow Jones Indices added three new members to the S&P 500 Dividend Aristocrats Index, expanding it to 69 companies. I rank Dividend Aristocrats by quality scores, presenting undervalued and overval...
Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS conference gets underway in Vegas.
AbbVie to Present at the Leerink Partners Global Healthcare Conference
NORTH CHICAGO, Ill. , March 4, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025.
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
On Monday, AbbVie Inc ABBV and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.
AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
AbbVie (ABBV) has agreed to license a weight-loss drug currently in development from Danish biotech firm Gubra for up to about $2.2 billion, signaling its entry in the obesity treatment market.
Final Trades: Taiwan Semi, Abbvie, Tradeweb Markets and the IYH
The Investment Committee give you their top stocks to watch for the second half.
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
HØRSHOLM, DK / ACCESS Newswire / March 03, 2025 / Gubra (CPH:GUBRA) Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide d...
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1 The primary endpoin...
AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
NORTH CHICAGO, Ill. , Feb. 26, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025.
Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here
Despite significant market events, industrial and tech stocks have had similar returns since 2020, indicating a potential long-term rotation favoring value stocks. Higher inflation and interest rates ...
Why AbbVie Remains A Strong Buy For Long-Term Investors
Why AbbVie Remains A Strong Buy For Long-Term Investors
How Dividend Investing Helps Parents Fund College Education Fees
More than half of parents in the United States emphasize paying for their child's college fees as a main concern. Start a UGMA custodial account early, and use the Dividend Growth Investing strategy t...